2020-2027 Analysis and Review Lidocaine Transdermal Patch Market

Lidocaine Transdermal Patch Market

Lidocaine Transdermal Patch Market By Clinical Application (Post-Herpetic Neuralgia, Joint Pain and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027

31-05-2020 REP-HC-5102 40 Tables 110 pages Format

The lidocaine transdermal patch market was valued at USD 508.4 Mn by 2019. Rising prevalence of Herpes zoster infection worldwide primarily drives the lidocaine transdermal patch market growth. Furthermore, increasing the geriatric population suffering from joint disorders will further increase the demand for lidocaine transdermal patches throughout the globe.

Lidocaine Transdermal Patch Market

Lidocaine is classified as a local anesthetic agent that exerts its pharmacological effect by preventing the nerves from sending the pain signals. It is manufactured as a transdermal patch with different strengths of 4%, 5%, etc. It is safer in comparison to oral analgesics, but before applying a transdermal patch the patient must consult the physician regarding any previous history of liver disease or allergy to lidocaine, its use must be prohibited in pregnant women owing to its side effects.

The major segments related to the lidocaine transdermal patch market are: 

By Clinical Application (2017–2027; US$ Mn)

Post-Herpetic Neuralgia

Joint Pain

Others

By Distribution Channel (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy

Others

Geography Segment (2017–2027; US$ Mn)

North America

U.S.
Canada

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

  • The intention of the study is to give a comprehensive outlook of the global lidocaine transdermal patch market
  • The overall segmentation of the lidocaine transdermal patch market, by clinical application, distribution channel, and geography is minutely studied. Post-herpetic neuralgia and hospital pharmacy are dominating the clinical application and distribution channel segments respectively
  • Growing incidence of postherpetic neuralgia in patients suffering with shingles infection worldwide
  • Rising prevalence of musculoskeletal disorders causing throbbing joint pain throughout the globe

Report gist?

  • The study of the global lidocaine transdermal patch market includes qualitative analysis of factors such as drivers, restraints, and opportunities
  • The report covers the qualitative and quantitative analysis of the overall market segmented on the basis of clinical application and distribution channel and categorization of the same at the geography level
  • This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. The compounded annual growth rate is calculated for the respective segments from 2020 to 2027

The study includes the profiles of major market players with a significant global and regional presence along with top company positioning. 

Significant customers?

  • This study is suitable for industry participants and stakeholders in the pharmaceutical manufacturers actively engaged in the production and marketing of lidocaine transdermal patch due to the growing incidence of post-herpetic neuralgia in patients suffering with shingles infection worldwide
  • The report will benefit formulation scientist engaged in the development of lidocaine transdermal patch to gain relief from joint pain
  • Managers with financial institutions looking to publish recent and forecasted statistics pertaining to lidocaine transdermal patch market
  • Financial institutions, venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies 

Segment Analysis

Post-herpetic neuralgia is representing the largest market share in the lidocaine transdermal patch market. The rising prevalence of shingles infection among the adult population worldwide primarily drives the market growth. It is also known as Herpes zoster infection, which recurs due to reactivation of the varicella-zoster viral infection. The most visible clinical manifestation of the shingles infection is the appearance of the rash in the trunk region along a thoracic dermatome, which is very painful and itchy. Joint pain is expected to record rampant market growth in the near future owing to the growing incidence of domestic accidents involving joint sprains and fractures. Additionally, increasing the geriatric population suffering from osteoporosis causing arthritis will further accentuate the market growth.

Hospital pharmacy is currently ruling the distribution channel segment in the lidocaine transdermal patch market. Significant rise in the number of patients visiting hospitals for the treatment of musculoskeletal disorders. Hospital pharmacists dispense different strengths of lidocaine transdermal patches as per the physician’s recommendation. Retail pharmacies are garnering huge popularity as a sales channel among consumers worldwide. Availability of lidocaine transdermal patches as an over the counter product (OTC) accentuates its market growth.

North America is presently dominating the geography segment for the lidocaine transdermal patch market. The growing incidence of post-neuralgia pain associated with shingles infection primarily drives the market growth in the region. According to the latest information provided by the Center for Disease Control and Prevention (CDC), the incidence rate for herpes zoster is 4 per 1000 people in the United States. Additionally, rising public health awareness pertaining to neuropathic pain and its treatment drives the lidocaine transdermal patch market growth in the region. Europe is the second-largest regional segment due to the significant increase in the geriatric population suffering from joint pains. As per the statistics provided by the European Commission report, approximately 40 million people across Europe are reported to be suffering from arthritis. The Asia Pacific is anticipated to be the fastest-growing regional segment during the forecast period. The constant rise in the injuries associated with sports and athletic activities and flourishing over the counter analgesics market together with determining the lidocaine transdermal patch market in the region.

Select License Type

$4,600
$6,600
$13,200

Safe and Secure SSL Encrypted

Have a Question?

We will help you find what you are looking for.

Call 1-518-730-1560

Contact sales

How can we help you?

Get in touch with us or find an office closest to you.